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1  | INTRODUC TION
Breast cancer is one of the most common cancers worldwide. In 2018, 
there were more than two million new cases, representing 11.6% of 
all new cancer cases.1 In terms of cause of death, it represents 6.6% 
of all deaths from cancer.1 From 2006 to 2016, the number of deaths 
from breast cancer increased by 17%, but age‐standardized mortality 
rates decreased by 9.9%.2 There was also a significant reduction of 
12.4% in the mean age‐standardized years of life lost rate in countries 
with high socio‐demographic index.2 Portuguese data showed that in 
2015, there were 1683 deaths due to breast cancer with an adjusted 
mortality rate of 19.3 (per 100 000).3 Treatment efficacy has been 
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Abstract
Aims: Cardiotoxicity is a possible complication of cancer treatment, particularly 
with anthracyclines and anti‐HER2 drugs. Systolic dysfunction has already been de‐
scribed. Diastolic dysfunction and left atrial function are less studied. We sought to 
analyze the impact of cardiotoxic treatments on left ventricular diastolic function and 
left atrial (LA) function.
Methods and Results: Retrospective study of 100 patients (all women, with a mean 
age of 54 ± 12 years) with three exams in the span of 1 year during treatment for 
breast cancer. Patients with previous cancer treatment, coronary artery disease, sig‐
nificant valvular disease, and atrial arrhythmias were excluded. Diastolic dysfunction 
was classified according to international guidelines and left atrial strain was analyzed 
by two‐dimensional speckle tracking. In our sample, 74% received anthracyclines, 
83% anti‐HER2, and 76% radiation treatment. In the follow‐up, 20% developed new 
or worsening diastolic dysfunction. Age was the only independent predictor (OR 
1.93, 95% CI 1.04–3.58, P = .037). In left atrial function, only the contractile function 
was significantly reduced in 20.8% of the patients and age was also the only inde‐
pendent predictor, but with a protective effect (OR 0.51, 95% CI 0.28–0.91, P = .023).
Conclusions: During breast cancer treatment, 20% of the patients develop new or 
worsening diastolic dysfunction, being age the main determinant, suggesting higher 
impact of chemotherapy in older patients. Contractile left atrial function is also com‐
promised but, in this case, age seems to be protective. Our results support a stricter 
surveillance in older patients together to eventually adjust chemotherapy regimens.
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increasing, and patient's survival and longevity have also improved. 
Cardiotoxicity is very common in breast cancer treatment, both early 
and late after treatment, and thus, cardiac surveillance is highly rec‐
ommended in these patients.4,5 Speckle‐tracking echocardiography 
(STE) has been validated as a quantitative assessment tool for left 
ventricular (LV) systolic function in this setting and is currently recom‐
mended in the surveillance of these patients during and after cancer 
treatment.4 Worsening of LV myocardial deformation is common in 
breast cancer patients undergoing chemotherapy, and an impaired 
Global Longitudinal Strain (GLS) in patients with preserved LV ejec‐
tion fraction is independently associated with increased incidence of 
chemotherapy‐induced cardiotoxicity and is thus an earlier predictor 
compared to the usual measurement of LV ejection fraction.4,6
Diastolic dysfunction is common in patients with cancer, both 
at baseline and during treatment, mainly related to the age group 
usually affected with cancer4; however, no evidence has shown that 
treatment should be stopped based on these findings.4 In fact, di‐
astolic parameters have not yet demonstrated value in predicting 
subsequent cardiotoxicity.
More recently, GLS by STE has been described for assessment 
of regional and global left atrial (LA) function.7 Atrial strain has been 
evaluated in multiple conditions, such as hypertension, diabetes, 
heart failure, ischemic and valvular heart disease, and atrial fibrilla‐
tion, including for assessment of prognostic implications.8‐14
It was our objective to evaluate in patients submitted to breast 
cancer treatment, the effect of treatment on LV diastolic function, 
its prognostic effect in subsequent LV systolic function, and the ef‐
fects in LA function as assessed by STE.
2  | METHODS
2.1 | Population
Retrospective analysis of all consecutive patients prospectively in‐
cluded in a single‐center echocardiographic registry of patients submit‐
ted to cardiotoxic agents in the setting of Oncology. Patient inclusion 
started in 2014, and all patients that performed at least three echocar‐
diograms in the span of 1 year in our laboratory during chemotherapy 
for breast cancer were included in the present analysis. Patients were 
excluded if they had a previous cancer treatment (with chemotherapy 
or radiotherapy), or in case, the treatment was started before the base‐
line echocardiographic assessment. A previous myocardial infarction, 
coronary revascularization, significant valvular heart disease, and atrial 
fibrillation/flutter or pacemaker were also exclusion criteria.
Hypertension was defined by a previous diagnosis or treatment 
with anti‐hypertensive drugs. Diabetes was defined by a previous 
diagnosis or treatment with anti‐diabetic drugs. Obesity was defined 
by a body mass index above 30 Kg/m2.
2.2 | Echocardiography
A complete standard echocardiographic study was performed using 
commercially available systems (Vivid 7™, Vivid 9™, and VividE95™; 
GE Healthcare). The patient was positioned in left lateral position, 
and the study was performed with a 3.5 MHz transducer. Left ven‐
tricular ejection fraction was assessed with the biplane method of 
disks (modified Simpson's rule).15 The following four variables were 
evaluated for identifying LV diastolic dysfunction: mitral annular e′ 
velocity (septal and lateral), average E/e′ ratio, LA maximum volume 
index, and tricuspid regurgitation peak velocity.16 LA volume was 
calculated with the biplane algorithm, which includes the 4‐chamber 
and 2‐chamber apical views.15 Diastolic dysfunction was classified 
according to the European Association of Cardiovascular Imaging 
(EACVI) guidelines.16 Left ventricular GLS was analyzed by two‐di‐
mensional STE. Images were acquired in the three standard apical 
views, and the transducer settings of the B‐mode image were ad‐
justed to achieve a frame rate of at least 55 frames per second (fps) 
(preferably set at 60–80 fps). Optimization of endocardial and myo‐
cardial definition was obtained by adjusting the gray scale. Images 
were digitally stored in cineloop format that included three sequen‐
tial beats and were transferred to a workstation for subsequent of‐
fline analysis using the software package EchoPAC™ (version 202, 
GE Healthcare). The borders of the LV endocardium were manually 
traced, and additional lines were automatically generated by the pro‐
gram near the epicardium. Speckles were traced during the cardiac 
cycle, in each frame. Whenever necessary, the region of interest was 
adjusted manually by the operator. Left ventricular GLS was the av‐
erage of all 18 segments. Left atrial strain was analyzed offline with 
the same software and with Q‐analysis. Thus, dedicated software 
for atrial analysis was not used. As recommended, LA longitudinal 
strain was obtained from an optimized apical 4‐chamber view of 
the LA.7 The 4‐chamber view was optimized in terms of orientation, 
depth, and gain, avoiding LA foreshortening and allowing visualiza‐
tion of the entire LA throughout the cardiac cycle. The region of in‐
terest size and shape was adjusted in order to include the thickness 
of LA wall. LA delineation was performed in a similar manner as for 
the LV, and it was manually edited if needed. Endocardial contour 
was extrapolated across the orifice of pulmonary veins and LA ap‐
pendage. Reference was placed at the onset of the R‐wave (R‐R gat‐
ing). With this specific gating, all strains are positive (Figure 1). There 
are two peaks that correspond to reservoir function (first peak—εR) 
and atrial contractile function (second peak—εCT). The difference 
between reservoir strain and atrial contractile strain values reflect 
conduit function (εCD). Strain measurements were made by a single 
operator. Because LA strain analysis is not performed with specific 
software, additional reproducibility analysis was performed.
Cancer treatment‐related cardiac dysfunction (cardiotoxicity) 
was defined by a reduction of 10% points in LV ejection fraction to a 
value below 50% (lower limit of normal) or by a relative percentage 
reduction of more than 15% of LV GLS from baseline.4 Because there 
are no cutoffs for LA cardiotoxicity, we considered significant a re‐
duction in the LA functional strain parameters above 15% to a value 
below the 10th percentile (calculated in the baseline evaluation) for 
each atrial function strain parameter.
All patients gave their informed consent to be included in the 
registry, and the study complies with the Helsinki declaration.
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2.3 | Statistical analysis
Assuming that 5% and 10% of the pairs have diastolic dysfunction in 
the first and second observation, respectively, that the correlation 
between paired observations is at least 70%, and applying continu‐
ity correction, the study would require a sample size of 68 pairs to 
achieve a power of 80% and a two‐sided significance of 5% to detect 
a difference of 0.10 between marginal populations. For that reason, 
100 patients are our ideal sample size. For LA strain analysis, with 
a smaller sample of 75 individuals (assuming that in 25% of the pa‐
tients it would not be possible to evaluate LA strain), with the same 
power and level of significance, assuming a correlation of 0.85 for LA 
strain parameters, we obtain an effect size of 1.796.
Continuous variables are expressed as mean and standard 
deviation. Normality and homogeneity of variance were tested 
with Kolmogorov‐Smirnov′s test and Levene's test, respectively. 
Categorical variables are reported as absolute frequencies and 
percentages. Differences between groups for categorical variables 
were tested with the chi‐square test or Fisher′s exact test, as appro‐
priate. For continuous variables, paired Student's t test was used.
Multivariate logistic regression models were used to assess the 
factors associated with LV diastolic dysfunction and LA dysfunc‐
tion. Factors that remained significant at the 0.10 level in univariate 
analysis were considered to be significant contributors and were 
included in the final models. Multicollinearity was also assessed 
and when identified, those variables were removed from the final 
multivariate model. Estimates of the association between predictors 
and endpoints are presented as odds ratio (OR) with 95% confidence 
interval (CI). The model's calibration was assessed with the Hosmer‐
Lemeshow test.
To establish and quantify reproducibility of LA strain analysis, 
agreement and intra‐ and inter‐observer reproducibility were as‐
sessed using the interclass correlation coefficient and reliability 
coefficients (Cronbach's alpha) with two‐way mixed effects models. 
Mean differences and limits of agreement were analyzed with Bland‐
Altman plots. Twenty‐five consecutive patients were selected for 
reproducibility analysis, and the two operators were blinded for pa‐
tient status and previous results.
IBM SPSS Statistics Software, version 19.0.0.2 (IBM SPSS Inc) 
was used for all statistical analysis. All statistical tests were two‐
sided with a critical value of 0.05 for statistical significance.
3  | RESULTS
3.1 | Population
From an initial sample of 111 patients, 11 were excluded due to pre‐
vious cancer treatment and the final sample included 100 patients, 
all females, with a mean age of 54 ± 12 years (28–83 years). The time 
interval between the first and second exam was 5.7 ± 1.8 months, 
and the third exam was performed 11.5 ± 2.3 months after the base‐
line. Baseline characteristics and cancer treatment are detailed in 
Table 1. All patients had a baseline LV ejection fraction > 50% and LV 
GLS > −18.5%. During treatment, three patients developed LV sys‐
tolic dysfunction as assessed by LV ejection fraction and 24 patients 
by LV GLS. Regarding treatment, the most commonly used chemo‐
therapy regimens were as follows: FEC × 3 (5‐fluorouracil, Epirubicin, 
Cyclophosphamide, with a maximum total dose of 300 mg/
m2 of epirubicin) followed by DTP × 3 (Doctaxel, Traztuzumab, 
Pertuzumab); AC × 4 (Doxorubicin, Cyclophosphamide, with a maxi‐
mum total dose of 240 mg/m2 of doxorubicin) followed by DT × 4 
(Docetaxel + Trastuzumab); TCH × 6 (Docetaxel, Carboplatin, 
Trastuzumab). In 81% of cases, these regimens were followed by 
1 year of trastuzumab alone every 21 days in the dose of 6 mg/Kg. 
Radiation treatment occurred at a median of 5 months after the 
baseline echocardiogram, and for that reason, the implications in LV 
diastolic function and LA function in the second echocardiographic 
evaluation were not analyzed.
F I G U R E  1   Left atrial strain analysis 
by speckle‐tracking echocardiography. 
εCD = conduit strain; εCT = contractile 
strain; εR = reservoir strain
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3.2 | Left ventricular diastolic function
During follow‐up, there was a significant increase in LA volume 
(Table 2). In regard to diastolic function, there was a steady worsen‐
ing from the baseline to the third echo examination (Table 2). In total, 
20 patients developed new or worsening diastolic dysfunction dur‐
ing treatment. In an exploratory analysis, the main potential predic‐
tors were age, hypertension, docetaxel use, and aromatase inhibitors 
use (Table 3). However, in multivariate analysis, only age remained 
as an independent predictor of diastolic dysfunction development. 
Neither anthracyclines use (OR 0.78, 95% CI 0.26–2.29), Anti‐HER2 
use (OR 0.45, 95% CI 0.15–1.40), nor both (OR 0.44, 95% CI 0.16–
1.21), nor radiation therapy (OR 1.44, 95% CI 0.38–5.57—comparison 
only for the third exam) nor LV systolic dysfunction development (OR 
1.20, 95% CI 0.41–3.54) was associated with LV diastolic dysfunction 
development/worsening during chemotherapy treatment.
In patients with baseline diastolic dysfunction, the risk of devel‐
opment of systolic cardiotoxicity during the 12 months follow‐up 
was not significant (OR 2.03, 95% CI 0.39–10.66). Patients with nor‐
mal LV systolic function in the second exam but that developed new 
or worsening diastolic dysfunction did not have an increased risk of 
cardiotoxicity in the third exam (OR 2.31, 95% CI 0.51–10.45).
There were no heart failure hospitalizations. In 37% of the patients, 
mild fatigue was reported and mild pedal edema in 7%. However, fa‐
tigue is a commonly reported side effect of chemotherapy and in most 
cases unrelated to heart failure. There was no association between 
fatigue and left ventricular diastolic dysfunction (only 35% of the pa‐
tients with fatigue had diastolic dysfunction, P = .836), and the same 
was observed for peripheral edema (10% of the patients with edema 
had diastolic dysfunction, P = .625). There was, however, some asso‐
ciation, as expected, with left ventricular systolic dysfunction (100% 
of patients with systolic dysfunction had fatigue, P = .048; 33% of the 
patients with systolic dysfunction had edema, P = .197).
3.3 | Left atrial function assessment
Reproducibility analysis showed excellent reproducibility both for 
intra‐ and inter‐observer, despite the use of a nondedicated software 
for LA strain analysis (Table S1). It was possible to assess LA strain in 
77 patients (53 ± 12 years). Risk factors and treatment proportions are 
similar to the main study group, as well as the time interval between 
studies. In this sample, it was also observed an increase in LA volume 
and LV systolic dysfunction during follow‐up (Table 4). However, we 
did not observe any significant worsening of mean left atrial function as 
assessed by strain analysis. The selected cutoff for εR was 16.8%, 8.0% 
for εCT, and 7.1% for εCD. The parameter that had more important 
worsening during treatment was εCT (Table 5). No factor was indepen‐
dently associated with εR or εCD reduction (Table 6). For εCT, it was 
only age that showed an inverse relationship. There was also a trend to 
be independently associated with baseline LV ejection fraction.
4  | DISCUSSION
During the first year of breast cancer treatment, there is a signifi‐
cant worsening in diastolic function, being age the only independ‐
ent predictor. Neither baseline diastolic dysfunction nor LV systolic 
dysfunction had any significant impact on LV diastolic dysfunction. 
Regarding LA function, the contractile function was the one that 
was more frequently compromised, being age a protective factor.
In breast cancer treatment, most regimens include the use of 
anthracyclines, taxanes, and inhibitors of human epidermal growth 
factor receptor 2 (anti‐HER2) drugs, which are associated with LV 
dysfunction.4 Anthracyclines can induce early cardiotoxicity due to 
cell necrosis (type I toxicity) and consequent myocardial dysfunc‐
tion.5 It causes irreversible cardiac damage and progressive cardiac 
remodeling as a late consequence.4,5 The most common hypothe‐
sis is the generation of reactive oxygen species, and lipid peroxi‐
dation of the cell membrane that damages the cardiomyocyte.4,5 
These agents have a cumulative dose relationship with cardiotoxic‐
ity. When a cumulative lifetime dose of doxorubicin (or equivalent) 
exceeds 400 mg/m2, the incidence of heart failure is up to 5%.4,5 
However, there is considerable variability among patients in their 
susceptibility.4 Early effects occur within the first year of treatment 
in about 98% of the cases.4 Currently, the doses in routine clinical 
TA B L E  1   Baseline characteristics and cancer treatment during 
the study




















Anthracyclines + Anti‐HER2 56 (56.0)
Trastuzumab + Pertuzumab 17 (17.0)
Neoadjuvant chemotherapy (%) 32 (32.0)
Radiation treatment (%) 76 (76.0)
Abbreviations: HER = human epidermal growth factor receptor.
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use were reduced, and typical cumulative exposure is now mostly 
in the 240–360 mg/m2 range for doxorubicin and 450–600 mg/m2 
for epirubicin.5 Cyclophosphamide cardiotoxicity is relatively rare, 
and it occurs within days of drug administration, with the same risk 
factors as for anthracyclines.4 Docetaxel, used frequently in com‐
bination with or after anthracyclines, cyclophosphamide or tras‐
tuzumab, also increases the incidence of heart failure.4 Taxanes 
also reduce doxorubicin elimination, resulting in higher plasmatic 
levels.4 In this regard, paclitaxel is more cardiotoxic that docetaxel. 
Anti‐HER2 drugs, such as trastuzumab and pertuzumab, can be 
given concomitantly with anthracyclines, but due to the high inci‐
dence of cardiotoxicity, it is more commonly used after anthracy‐
clines or using an anthracycline‐free chemotherapy regimen with 
antimetabolites or alkylating agents.4 In contrast to other agents, 
trastuzumab toxicity manifests during treatment and unlike anthra‐
cyclines, long‐term studies are reassuring in terms of absence of late 
effects and it is not cumulative dose‐related.4 A drug‐free interval 
between the two agents is recommended.4,5 With this drug, cardiac 
dysfunction appears to rise from impairment of contractility due to 
cell dysfunction (type II toxicity) rather than loss of myocytes and is 
potentially reversible.5
Regarding radiotherapy, there is a longtime delay between expo‐
sure and clinical manifestation of radiation‐induced cardiotoxicity and 
it results from marked interstitial myocardial fibrosis.4 Also, continu‐
ous improvements in radiation techniques are reducing its incidence.4 
In general, the main risk factors for cardiotoxicity are the cumula‐
tive dose of some drugs (such as anthracyclines), age above 65 years, 
preexisting cardiac diseases leading to increased wall stress, arterial 
hypertension, concomitant use of mediastinal radiation and/or a 
concomitant or incorrect timing of administration of multiple cancer 
drugs (alkylating, antimicrotubule agents, and particularly immuno‐
therapy and targeted therapies) with potential for cardiotoxic effects 
from interactions among the different therapeutic modalities.4,5
If all these drugs have an effect on LV myocyte, they can also in‐
duce diastolic dysfunction (that can potentially be used as an earlier 
indicator of progressive LV systolic dysfunction), or LA dysfunction. 
However, diastolic parameters have not yet demonstrated value in 
predicting subsequent chemotherapy‐related cardiotoxicity. E/e′ ratio 
TA B L E  2   Echocardiographic results for diastolic function
Variable Echo 1 Echo 2 P‐value Echo 3 P‐value (2 vs 3) P‐value (1 vs 3)
Mitral E (cm/s) 76 ± 19 78 ± 18 .249 76 ± 18 .240 1.000
Mitral A (cm/s) 75 ± 19 76 ± 18 .691 74 ± 18 .292 .565
Mitral E/A 1.0 ± 0.4 1.1 ± .3 .491 1.1 ± 0.3 .622 .799
Mitral DecT (m/s) 209 ± 52 191 ± 40 .060 191 ± 54 .996 .018
Mitral E′s (cm/s) 8.2 ± 2.6 8.1 ± 2.4 .822 8.1 ± 2.4 1.000 .568
Mitral E′l (cm/s) 11.4 ± 3.2 11.2 ± 3.2 .445 11.0 ± 3.2 .214 .310
Mitral E′ mean (cm/s) 9.9 ± 2.6 9.7 ± 2.7 .441 9.6 ± 2.5 .509 .290
E/E′ 8.1 ± 2.4 8.5 ± 2.3 .177 8.3 ± 2.6 .651 .311
TR vel (m/s) 2.3 ± 0.3 2.4 ± 0.3 .490 2.4 ± 0.3 .097 .454
LA/BSA (mL/m2) 24 ± 7 25 ± 7 .115 27 ± 9 .100 .003
LVEF (%) 64 ± 6 62 ± 7 .004 61 ± 7 .424 <.001
LV GLS (%) −20.0 ± 3.2 −19.0 ± 3.0 .031 −18.6 ± 2.6 .256 .001
Diastolic dysfunction (%)   .217  .077 .030
Normal 94 88  84   
Grade 1 6 12  11   
Grade 2 0 0  5   
Abbreviations: BSA = body surface area; DecT = deceleration time; LA = left atrial; LVEF = left ventricular ejection fraction; LVGLS = left ventricular 





P‐valueOdds ratio (95% CI) Odds ratio (95% CI)
Age (per 10‐y 
increase)
2.79 (1.65–4.71) <.001 1.93 (1.04–3.58) .037
Hypertension 7.49 (2.53–22.2) <.001 2.74 (0.74–10.19) .132
Docetaxel 0.36 (0.12–1.08) .068 0.49 (0.13–1.89) .301
Aromatase inhibitor 3.86 (1.35–11.06) .012 2.04 (0.59–7.12) .262
TA B L E  3   Logistic regression analysis 
for predictors of left ventricular diastolic 
dysfunction development
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remains questionable in the oncology setting because there might be 
E velocity fluctuations as a consequence of changes in loading condi‐
tions associated to side effects of chemotherapy (nausea, vomiting, 
and diarrhea) and not as a result of real change in left ventricular di‐
astolic performance.17 In this regard, e′ is more independent of pre‐
load.17 In our sample, we demonstrated a significant worsening of 
diastolic function during treatment. However, the main determinant 
of worsening was age and this is in accordance with previous obser‐
vations of LV systolic cardiotoxicity being more frequent in patients 
older than 65 years.4 We can conclude that these agents are more 
detrimental in older individuals, and thus, a more strict surveillance 
should be undertaken in those patients for early detection of those 
changes and to decide on the need to use less aggressive regimen. In 
our sample, we also did not observe a significant relationship between 
diastolic dysfunction development/worsening and LV systolic dys‐
function during follow‐up, and for that reason, no recommendations 
about treatment interruption can be suggested.
Left atrial indexed volume remains the main echocardiographic pa‐
rameter to assess the remodeling and indirectly the function of the LA 
and is a powerful prognostic tool.17‐20 However, volumetric measures 
of LA function are limited by lower sensitivity in early disease states 
and can be increased due to other diseases.19 LA myocardial analysis 
using 2DSTE identifies LA dysfunction despite normal LA ejection 
fraction and normal LA indexed volume in patients with LV diastolic 
dysfunction.17 Thus, myocardial LA analysis using 2DSTE has several 
advantages over volumetric LA measurements. The advantages of left 
atrial strain by STE are the rapid and easy performance, angle inde‐
pendence, it is less affected by side lobes, reverberations and dropout 
artifacts, the possibility of offline processing, and provides qualitative 
assessment of LA function.17 The main disadvantages are the frame 
rate dependence, the potential errors in epicardial/endocardial border 
tracing and the absence of a dedicated analysis software.17 Unlike LV 
strain, LA strain using STE has not been validated, but there is a growing 
body of outcome data supporting its diagnostic and prognostic value.8‐
14 Our results showed very good reproducibility with the technique.
LA strain parameters are usually higher in women, compared to 
men.21 With increasing age, it decreases progressively, being more pro‐
nounced in women, and independently of baseline characteristics such 
TA B L E  4   Echocardiographic results for the left atrial analysis
Variable Echo 1 Echo 2 P‐value Echo 3 P‐value (2 vs 3) P‐value (1 vs 3)
Mitral E (cm/s) 76 ± 20 77 ± 20 .379 75 ± 19 .168 .641
Mitral A (cm/s) 75 ± 19 74 ± 17 .617 73 ± 18 .584 .271
Mitral E/A 1.1 ± 0.4 1.1 ± 0.3 .673 1.1 ± 0.3 .460 .817
Mitral DecT (m/s) 208 ± 48 192 ± 42 .026 193 ± 58 .898 .082
Mitral E′s (cm/s) 8.1 ± 2.7 8.2 ± 2.4 .629 8.0 ± 2.4 .281 .464
Mitral E′l (cm/s) 11.5 ± 3.1 11.3 ± 3.2 .627 11.0 ± 3.2 .257 .217
Mitral E′ mean (cm/s) 9.9 ± 2.6 9.8 ± 2.6 .882 9.6 ± 2.5 .199 .227
E/E′ 8.1 ± 2.4 8.3 ± 2.3 .425 8.3 ± 2.7 .866 .473
TR vel (m/s) 2.3 ± 0.3 2.3 ± 0.3 .716 2.4 ± 0.3 .432 .730
LA/BSA (mL/m2) 24 ± 7 25 ± 7 .563 27 ± 9 .044 .014
LVEF (%) 64 ± 7 62 ± 7 .011 60 ± 7 .139 <.001
LV GLS (%) −19.7 ± 3.3 −19.0 ± 3.0 .177 −18.6 ± 2.5 .422 .017
Diastolic dysfunction n(%)   1.000  .084 .060
Normal 72 (93.5) 71 (92.2)  64 (83.1)   
Grade 1 5 (6.5) 6 (7.8)  9 (11.7)   
Grade 2 0 0  4 (5.2)   
LA strain (%)
εR 30.8 ± 11.3 31.3 ± 10.2 .741 30.5 ± 10.9 .601 .822
εCT 13.2 ± 4.5 13.0 ± 4.3 .818 12.5 ± 4.5 .409 .286
εCD 17.7 ± 8.7 18.2 ± 8.5 561 18.0 ± 8.6 .827 .753
Abbreviations: εCD = LA conduct strain; εCT = LA contractile strain; εR = LA reservoir strain; BSA = body surface area; DecT = deceleration time; 
LA = left atrial; LVEF = left ventricular ejection fraction; LVGLS = left ventricular global longitudinal strain; TR = tricuspid regurgitation.
n (%) Reduction 1–2 Reduction 2–3 Reduction 1–3 Total reduction
εR 3 (3.9) 8 (10.4) 7 (9.1) 11 (14.3)
εCT 8 (10.4) 9 (11.7) 8 (10.4) 16 (20.8)
εCD 7 (9.1) 6 (7.8) 4 (5.2) 13 (16.9)
Abbreviations: εCD = LA conduit strain; εCT = LA contractile strain; εR = LA reservoir strain.
TA B L E  5   Significant changes in left 
atrial strain parameters
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as blood pressure, LA volume or LV diastolic function.17‐21 With increas‐
ing age, impaired LV relaxation reduces passive atrial conduit function 
and LA stiffness decreases reservoir function, limiting LV filling.21 With 
senescence, LA contraction augments as a compensatory mechanism 
with a late decrease with further aging.21 The same changes are re‐
ported with LV diastolic dysfunction.22,23 In early stages, LA reservoir 
and conduit strain decreases and an increase in its booster function 
can compensate filling. But with prolonged dysfunction, LA dilation oc‐
curs, and eventually, LA mechanical function shows a fall in the relative 
contribution of LA pump to LV filling. This is particularly important for 
heart failure with preserved ejection fraction progression because LA 
strain parameters are independently associated with abnormal exercise 
hemodynamics.24 Some authors suggest the use of LA reservoir strain 
(peak LA strain) as a promising prognostic marker in heart failure.25
Our baseline values for all strain parameters, with the exception 
of εCD, were lower in comparison with the normal values reported 
in the literature.19 Our explanation is the difference in baseline char‐
acteristics of our sample in comparison with the healthy subjects 
analyzed in the meta‐analysis that defined normal LA strain values. 
Reference values for LA strain were defined for patients without 
cardiovascular risk factors. Our sample has several patients with an 
age > 60 years, hypertension and baseline diastolic dysfunction that 
was not present in the previous meta‐analysis.
We observed a substantial reduction in LA contractile function in 
more than 20% of the patients, although all other parameters were 
also changes but in fewer patients. The reduction in contractile func‐
tion was only independently associated with age, being in that case 
protective. As previously mentioned, age is one of the most import‐
ant predictors of LA dysfunction, independently of other character‐
istics such as LV diastolic dysfunction and as such, our results are in 
accordance with previous reports. Thus, the most likely explanation 
is that, as previously mentioned, εR and εCD usually deteriorate with 
increasing age, but contractile function is positively correlated with 
age (increases with age).19,21 Augmented LA active contraction oc‐
curs as a compensatory mechanism with senescence.19,21 For that 
reason, in older patients, we expect a less significant or delayed 
decrease in LA contractile function by strain analysis, justifying the 
inverse independent association observed.
4.1 | Limitations
Although our sample size is adequate according to our sample size 
analysis, it is, nonetheless, relatively small. For that reason, our re‐
sults require confirmation in larger samples.
This is a retrospective study, and strain measurements were not 
a prespecified test in routine evaluation. Thus, a significant number 
of patients did not have adequate images for strain analysis. Our fea‐
sibility was 77%, a little lower compared to other studies that report 
exclusion rates around 15% due to poor image quality. In our case, the 
main reason was inadequate storing of images and not image quality.
Intervendor variability is a problem previously reported in strain 
analysis with speckle tracking. However, in the previously men‐
tioned meta‐analysis for the LA strain reference values, they found 
no significant differences between vendors.19
Another potential limitation of left atrial strain is LA wall thin‐
ness, with the possibility of wall dropout and poor tissue tracking.
5 | CONCLUSION
In our sample of women with breast cancer, during the first year 
of breast cancer treatment, there is a significant worsening in di‐
astolic function, being age the only independent predictor. Neither 
baseline diastolic dysfunction nor LV systolic dysfunction had any 
 





Docetaxel 0.21 (0.06–0.84) .027 0.26 (0.06–1.10) .067
Diastolic dysfunction 3.20 (0.79–12.98) .100 2.19 (0.45–9.89) .307
Significant εCD change
Hypertension 3.81 (1.11–13.10) .034 2.34 (0.51–10.82) .277
Docetaxel 0.30 (0.08–1.09) .068 0.40 (0.10–1.64) .201
Anastrazol 4.30 (1.01–18.26) .048 2.78 (0.55–13.94) .213
Diastolic dysfunction 3.82 (1.02–14.31) .047 1.34 (0.23–7.68) .741
Significant εCT change
Age (per 10‐y increase) 0.55 (0.32–0.95) .031 0.51 (0.28–0.91) .023
Baseline LVEF 1.08 (0.99–1.18) .066 1.11 (1.00–1.23) .055
Pertuzumab 3.06 (0.91–10.34) .072 2.31 (0.49–10.85) .287
Neoadjuvant chemotherapy 3.94 (1.25–12.41) .019 2.68 (0.66–10.95) .170
Abbreviations: εCD = left atrial conduit strain; εCT = left atrial contractile strain; εR = left atrial 
reservoir strain; CI = confidence interval; LVEF = left ventricular ejection fraction; OR = odds ratio.
TA B L E  6   Factors associated with 
left atrial strain parameters significant 
changes
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significant impact on LV diastolic dysfunction. Regarding LA func‐
tion, the contractile function was the one that was more frequently 





Ana Teresa Timóteo  https://orcid.org/0000‐0001‐6061‐9663 
REFERENCES
 1. World Health Organization. The Global Cancer Observatory. 
Available from: gco.iarc‐fr/total/data/factsheets/cancer/20‐
Breast‐fact‐sheet.pdf
 2. GBD 2016 Causes of Death Collaborators. Global, regional, and 
national age‐sex–specific mortality for 269 causes of death, 
1980‐2016: a systematic analysis for the Global Burden of Disease 
Study 2016. Lancet. 2017;390:1151–1210.
 3. General Directorate of Health. Programa Nacional para doenças 
oncológicas. Available from: www.dgs.pt
 4. Zamorano JL, Lancelloti P, Asteggiano R, et al. 2016 ESC position 
paper on cancer treatments and cardiovascular toxicity developed 
under the auspices of the ESC committee for practice guidelines. 
Eur Heart J. 2016;37:2768–2801.
 5. Eschenhagen T, Force T, Ewer M, et al. Cardiovascular side effects 
of cancer therapies: a position statement from the Heart Failure 
Association of the European Society of Cardiology. Eur J Heart Fail. 
2011;13:1–10.
 6. Portugal G, Moura Branco L, Galrinho A, et al. Global and regional 
patterns of longitudinal strain in screening for chemotherapy‐in‐
duced cardiotoxicity. Rev Port Cardiol. 2017;36:9–15.
 7. Badano LP, Kolias TJ, Muraru D, et al. Standardization of left atrial, 
right ventricular, and right atrial deformation imaging using two‐
dimensional speckle tracking echocardiography: a consensus 
document of the EACVI/ASE/Industry Task Force to standardize de‐
formation imaging. Eur Heart J Cardiovasc Imaging. 2018;19:591–600.
 8. Cameli M, Ciccione MM, Maiello M, et al. Speckle‐tracking analysis: 
a new tool for left atrial function analysis in systemic hypertension: 
an overview. J Cardiovasc Med. 2016;17:339–343.
 9. Mondillo S, Cameli M, Caputo NL. Early detection of left atrial 
strain abnormalities by speckle tracking in hypertensive and di‐
abetic patients with normal left atrial size. J Am Soc Echocardiogr. 
2011;24:898–908.
 10. Malagoli A, Rossi L, Bursi F, et al. Left atrial function predicts car‐
diovascular events in patients with chronic heart failure with re‐
duced ejection fraction. J Am Soc Echocardiogr. 2019;32:248–256.
 11. Antoni ML, Ten Brinke EA, Marsan MA. Comprehensive assessment 
of changes in left atrial volumes and function after ST‐segment ele‐
vation acute myocardial infarction: role of two‐dimensional speckle 
tracking strain imaging. J Am Soc Echocardiogr. 2011;24:1126–1133.
 12. Todaro MC, Carerg S, Khandheria B, et al. Usefulness of atrial func‐
tion for risk stratification in asymptomatic severe aortic stenosis. J 
Cardiol. 2016;67:71–79.
 13. Mochizuki A, Yuda S, Oi Y, et al. Assessment of left atrial defor‐
mation and synchrony by three‐dimensional speckle‐tracking echo‐
cardiography: comparative studies in healthy subjects and patients 
with atrial fibrillation. J Am Soc Echocardiogr. 2013;26:165–174.
 14. Obokata M, Negishi K, Kurosava K, et al. Left atrial strain provides 
incremental value for embolism risk stratification over CHA(2)
DS(2)‐VASc score and indicates prognostic impact in patients with 
atrial fibrillation. J Am Soc Echocardiogr. 2014;27:709–716.
 15. Lang RM, Badano LP, Mor‐Avi V, et al. Recommendations for cardiac 
chamber quantification by echocardiography in adults: an update 
from the American Society of Echocardiography and the European 
Association of Cardiovascular Imaging. Eur Heart J Cardiovasc 
Imaging. 2015;16:233–271.
 16. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for 
the evaluation of left ventricular diastolic function by echocardiog‐
raphy: an update from the American Society of Echocardiography 
and the European Association of Cardiovascular Imaging. Eur Heart 
J Cardiovasc Imaging. 2016;17:1321–1360.
 17. Cameli M, Mandoli GE, Loiacono F, et al. Left atrial strain: a new 
parameter for assessment of left ventricular filling pressure. Heart 
Fail Rev. 2016;21:65–76.
 18. Morris DA, Takeuchi M, Krisper M, et al. Normal values and clin‐
ical relevance of left atrial myocardial function analyzed by 
speckle‐tracking echocardiography: multicenter study. Eur Heart J 
Cardiovasc Imaging. 2015;16:364–372.
 19. Pathan F, D'Elia N, Nolan M, et al. Normal ranges of left atrial strain 
by speckle‐tracking echocardiography: a systematic review and 
meta‐analysis. J Am Soc Echocardiogr. 2017;30:59–70.
 20. Meel R, Khandheria BK, Peters F, et al. Effects of age on left atrial 
volume and strain parameters using echocardiography in a normal 
black population. Echo Res Pract. 2016;3:115–123.
 21. Liao JN, Chao TF, Kuo JY, et al. Age, sex, and blood pressure‐re‐
lated influences on reference values of left atrial deformation and 
mechanics from a large scale Asian population. Circ Cardiovasc 
Imaging. 2017;10:e006077. https ://doi.org/10.1161/CIRCI 
MAGING.116.006077
 22. Saikhan LA, Hughes AD, Chung WS, et al. Left atrial function in 
heart failure with mid‐range ejection fraction differes from that 
of heart failure with preserved ejection fraction: a 2D speckle‐
tracking echocardiographic study. Eur Heart J Cardiovasc Imaging. 
2019;20:279–290.
 23. Reddy Y, Obokata M, Egbe A, et al. Left atrial strain and compliance 
in the diagnostic evaluation of heart failure with preserved ejection 
fraction. Eur J Heart Fail. 2019;21:891–900.
 24. Telles F, Nanayakkara S, Evans S, et al. Impaired left atrial strain 
predicts abnormal exercise haemodynamics in heart failure with 
preserved ejection fraction. Eur J Heart Fail. 2019;21:495–505.
 25. Thomas L, Marwick TH, Popescu BA, et al. Left atrial structure and 
function, and left ventricular diastolic dysfunction. J Am Coll Cardiol. 
2019;73:1961–1977.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section at the end of the article.
Table S1. Reproducibility analysis for left atrial strain by 2‐dimen‐
sional speckle tracking echocardiography.
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